What are the possible causes of borderline Concentric Left Ventricular (LV) Hypertrophy, Mild Systolic Anterior Motion (SAM), and Trace Mitral Regurgitation, and can they be caused by anxiety and stress?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: March 13, 2025 • View editorial policy

From the Guidelines

Borderline concentric left ventricular hypertrophy, mild systolic anterior motion, and trace mitral regurgitation are most likely caused by chronic hypertension, hypertrophic cardiomyopathy, or athletic heart syndrome, rather than directly by anxiety and stress. The possible causes of these conditions are numerous and can be attributed to various systemic disorders, including metabolic and multiorgan syndromes, as well as secondary causes of left ventricular hypertrophy (LVH) such as remodeling secondary to athletic training or long-standing systemic hypertension 1. Some key points to consider include:

  • The magnitude and distribution of increased left ventricular wall thickness can be similar to that of isolated hypertrophic cardiomyopathy (HCM) caused by variants in sarcomeric genes, but the pathophysiologic mechanisms responsible for hypertrophy, natural history, and treatment strategies are not the same 1.
  • Other cardiac or systemic diseases capable of producing LVH should not be labeled as HCM and can include conditions such as hemodynamic obstruction caused by left-sided obstructive lesions or obstruction after antero-apical infarction and stress cardiomyopathy 1.
  • Anxiety and stress can contribute to hypertension, which over time could lead to LVH, but they typically do not directly cause structural heart abnormalities like LVH or systolic anterior motion (SAM) 1.
  • A number of clinical markers and testing strategies can be used to help differentiate between HCM and conditions of physiologic LVH, including the pattern and distribution of LV wall thickening, as well as the presence of other morphologic abnormalities such as hypertrophied and apically displaced papillary muscles or myocardial crypts 1. It is essential to conduct further clinical evaluation to determine the specific underlying cause and appropriate management of these conditions.

From the Research

Possible Causes of Borderline Concentric Left Ventricular (LV) Hypertrophy

  • Borderline concentric LV hypertrophy can be caused by hypertension, as it is a maladaptive response to chronic pressure overload 2
  • Other possible causes include mitral annulus calcification, which can lead to systolic anterior motion of the anterior leaflet of the mitral valve and left ventricular outflow tract obstruction 3
  • Mild hypertensive heart disease can also cause borderline concentric LV hypertrophy, systolic anterior motion, and left ventricular outflow tract obstruction 4

Relationship between Anxiety, Stress, and Borderline Concentric LV Hypertrophy

  • There is no direct evidence in the provided studies to suggest that anxiety and stress can cause borderline concentric LV hypertrophy, mild systolic anterior motion, and trace mitral regurgitation
  • However, it is known that hypertension is a major risk factor for left ventricular hypertrophy, and anxiety and stress can contribute to hypertension

Risk Factors for Progression to Systolic Dysfunction

  • Interval myocardial infarction, QRS prolongation, and elevated follow-up arterial impedance are risk factors for developing left ventricular systolic dysfunction in patients with concentric LV hypertrophy and a normal ejection fraction 5
  • Hypertension, left ventricular hypertrophy, and sudden cardiac death are also related, with left ventricular hypertrophy being a powerful, independent predictor of atrial fibrillation, ventricular arrhythmias, and sudden cardiac death 6

Treatment and Management

  • Controlling arterial pressure, sodium restriction, and weight loss can facilitate the regression of left ventricular hypertrophy 2
  • Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, followed by calcium channel antagonists, can also facilitate the regression of left ventricular hypertrophy 2
  • Angiotensin II antagonists may be considered as the treatment of choice for patients with mild hypertensive heart disease and left ventricular outflow tract obstruction 4

Related Questions

Does this patient require urgent follow-up due to risks associated with borderline Concentric Left Ventricular (LV) Hypertrophy and Mild Systolic Anterior Motion (SAM), or can these findings be attributed to anxiety and stress?
Will Mild Systolic Anterior Motion (SAM) of the mitral valve and Borderline Concentric Left Ventricular Hypertrophy (CLVH) progress or resolve spontaneously in a 20-year-old male patient with normal cholesterol levels and no symptoms, and are these findings related to Erectile Dysfunction (ED) or caused by anxiety and stress?
What is the overall assessment of cardiac function given normal Left Ventricular (LV) systolic function, normal Left Ventricular (LV) diastolic filling pressure, and normal Right Ventricular (RV) systolic function?
What is the interpretation and management plan for an EKG showing left ventricular hypertrophy, probable left atrial enlargement, and possible anterior Q waves?
What is the most appropriate initial antihypertensive medication for a patient with hypertension and left ventricular hypertrophy?
What is the role of filgrastim (Granulocyte-Colony Stimulating Factor, G-CSF) in mitigating methotrexate (MTX) toxicity?
Does this patient require urgent follow-up due to risks associated with borderline Concentric Left Ventricular (LV) Hypertrophy and Mild Systolic Anterior Motion (SAM), or can these findings be attributed to anxiety and stress?
What is the timeframe for D-dimer (D-dimer) levels to normalize after pregnancy?
What is the treatment for hyperkalemia (elevated potassium levels)?
What is the next step for a patient with a third-degree atrioventricular (AV) block detected on telemetry?
What is the time difference between administration of cytarabine and methotrexate in Hyperfractionated Cyclophosphamide, Vincristine (Oncovin), Doxorubicin (Adriamycin), and Dexamethasone (HyperCVAD)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.